Introduction {#s01}
============

Worldwide, esophageal cancer is one of the most aggressive tumors, and is highly prevalent in China ([@b1],[@b2]). It is the 4th leading cause of cancer-related mortality in China, where esophageal squamous cell carcinoma (ESCC) is the major histological type ([@b3],[@b4]). There are advances in the early detection and treatment of patients with ESCC, but the 5-year survival of global ESCC patients is still very poor ([@b5],[@b6]). Several large-scale analyses demonstrated that some genes and pathways, such as *TP53*, *RB1*, *CDKN2A*, *PIK3CA*, *Notch* and FAT atypical cadherin 1 (*FAT1*), may contribute to ESCC tumorigenesis ([@b7]-[@b11]).Among these aberrant genes, the "sleeping giant" ([@b12]) *FAT1* is inactivated by a two-hit model in ESCC tumors, where somatic mutations are often accompanied by the loss of heterozygosity or homozygous deletion ([@b9],[@b11]), showing an anti-tumor activity ([@b9],[@b13],[@b14]). *FAT1* encodes a cadherin-like trans-membrane protein and regulates the cell-cell contact, polarization, migration and growth of mammalian cells ([@b15]-[@b17]). Interestingly, *FAT1* may function as both a tumor suppressor and an oncogene depending on different cell context ([@b18]-[@b21]). The inactivation of *FAT1* via somatic mutations or deletions is also observed in multiple human cancers to promote Wnt/β-catenin signaling and tumorigenesis ([@b18]). Other mechanisms regulating *FAT1* expression remain poorly understood and need further investigation.

Transcriptional regulation by transcription factors is a critical way to affect gene expression. E2Fs are a large family of transcription factors that modulate gene expression by acting as either activators or repressors of transcription based on their structures and functions ([@b22],[@b23]). In Homo sapiens, E2F transcription factor 1 (E2F1), which is the first member of the E2F family, is characterized as an activating transcription factor to mediate various biological processes, including cell cycle progression, apoptosis, DNA-damage response and metastasis ([@b24]-[@b27]). E2F1 binds to promoters of target genes, such as G1/S regulated genes and apoptosis-related genes, to regulate their expression ([@b28]-[@b30]), predominantly by interacting with the RB pocket protein ([@b31]). Advances in high-throughput technologies reveal that E2F1 also occupies a large fraction of gene promoters ([@b32]), suggesting that it has a wide spread regulation role in the human genome. However, the transcriptional regulation of E2F1 on the *FAT1* locus remains unknown.

In this study, we comprehensively analyzed the genetic alterations of *FAT1* in ESCC, as well as its copy number variants (CNVs) in other cancers. More importantly, the transcriptional regulation of *FAT1* by E2F1 was elaborated. In addition, the effects of *FAT1* on cell proliferation, migration and invasion were also monitored in ESCC cells. Finally, RNA sequencing (RNA-seq) was performed to investigate the gene expression profile upon *FAT1* knockdown.

Materials and methods {#s02}
=====================

Cell lines {#s02.01}
----------

ESCC cell lines, KYSE30, KYSE150 and KYSE410, were generous gifts from Prof. Y Shimada of Kyoto University, Japan. All cell lines were cultured at 37 °C with 5% CO~2~ in RPMI 1640 medium (Gibco) with 10% fetal bovine serum (FBS).

Cell transfection {#s02.02}
-----------------

Cells at the logarithmic growth phase were transfected with siRNAs or plasmids using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions. All siRNAs (25-mer duplex Stealth siRNAs) were obtained from Invitrogen, and the sequence information is as follows: siFAT1: HSS103568 and HSS176716 and siE2F1: HSS103016 and HSS103017. The FAT1-Trunc plasmid, which contains all key functional domains of FAT1 ([@b18]), was a generous gift from Dr. Luc GT Morris (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center).

Chromatin immunoprecipitation (ChIP) {#s02.03}
------------------------------------

Pierce Magnetic ChIP Kit (Thermo Fisher, Waltham, USA) was used according to the manufacturer's instructions. Briefly, KYSE30 cells were cross-linked with formaldehyde and the nucleus was isolated. Chromatin DNA was fragmented and incubated with E2F1 antibody (ab179445; Abcam, Cambridge, UK) followed by addition of magnetic beads. After washing and purification, the precipitated chromatins were analyzed by quantitative polymerase chain reaction (qPCR). The primers targeting the *FAT1* promoter were synthesized by Invitrogen, and the sequences are as follows: forward 5'-GGAGCTCACCCGCCGTCTCA-3' and reverse 5'-GCTCGTGCGGCAGGTACCA-3'.

Luciferase reporter assay {#s02.04}
-------------------------

To obtain the pGL3-FAT1 vector, the promoter region of *FAT1*, ranging from −2000 bp to +500 bp, was synthesized and inserted into the pGL3-Basic vector by Generay (Shanghai, China). Then, KYSE30 cells were co-transfected by pGL3-FAT1 vector and pRL-TK Renilla vector together with E2F1 siRNA. After 36 h of transfection, the luciferase activity was detected by the Dual-Luciferase Reporter Assay System (Promega, USA), and the Firefly luciferase activity was normalized to the Renilla luciferase activity.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) {#s02.05}
-----------------------------------------------------------------------------------------

Total RNA from ESCC cells was purified using RNAiso plus (Takara, Dalian, China). Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using a PrimeScript^®^ RT reagent Kit with gDNA Eraser (Takara). TB Green^®^ Premix Ex Taq^®^ II kit (Takara) was used to detect the indicated RNA levels on the QuantStudio Real-Time PCR System (Applied Biosystems, USA) or the CFX96 Real-Time System (Bio-Rad, USA). The relative expression levels of the target genes were normalized to endogenous GAPDH. The primers synthesized by Invitrogen are listed in *[Supplementary Table S1](#TableS1){ref-type="table"}*.

###### 

Primer sequences for RT-qPCR

  Primer         Sequences
  -------------- ---------------------------
  GAPDH-F        GGTCATCCATGACAACTTTGGTATC
  GAPDH-R        GTAGAGGCAGGGATGATGTTCTG
  FAT1-F         GGTCCAGATCGAGGCATTTGA
  FAT1-R         TCATCTTGCTGTTCTCGGTCTAG
  FAT1-Trunc-F   GGCGTTTGGATCTGCTGAGTA
  FAT1-Trunc-R   GTCTCTGAGCTCCTTCCAGTC
  E2F1-F         GCTGGACCTGGAAACTGACC
  E2F1-R         TCATAGCGTGACTTCTCCCCC
  MAP3K8-F       CCGGGCAGTCTCTTTCTGTT
  MAP3K8-R       GCTCTGCCCCTGACTCAC
  MAP2K2-F       TATTGTGAACGAGCCACCTCC
  MAP2K2-R       TTACACAACCAGCCGGCAAA
  MAP2K6-F       GCCGAAGTGTGGTCTTTGGA
  MAP2K6-R       CTGCAGTTCGCTTACTTGCC
  DUSP6-F        ATGGACCGACTGTACCGTGT
  DUSP6-R        ACATGTGGCTGTCATCTTGGT
  L1CAM-F        ATCATCCTCCTGCTCCTCGT
  L1CAM-R        TCTCCAGGGACCTGTACTCG
  CDH5-F         ATGAGATCGTGGTGGAAGCG
  CDH5-R         ATGTGTACTTGGTCTGGGTGA

Western blot {#s02.06}
------------

Total protein from ESCC cells was extracted using RIPA lysis buffer (Proteintech Group, Wuhan, China) that was supplemented with the protease inhibitor PMSF and was quantified by Enhanced BCA Protein Assay Kit (Beyotime Institute of Biotechnology, Shanghai, China) following the manufacturer's protocols. Equal quantities of proteins were separated by 10% SDS-PAGE and were transferred onto PVDF membranes. After blocking in 5% non-fat milk for 1 h, the membrane was then incubated with E2F1 primary antibody (ab179445; Abcam) at 4 °C overnight. Protein bands were detected using a horseradish-peroxidase (HRP)-conjugated IgG secondary antibody (Proteintech Group), and images were captured with the BioSpectrum imaging system (UVP, USA). GAPDH (60004-1-lg; Proteintech Group) was used as loading control.

In-cell western assay {#s02.07}
---------------------

Cells grown in 96-well plates were fixed with 3.7% formaldehyde for 20 min and were permeabilized using 0.1% Triton X-100. After blocking with 5% non-fat milk for 1 h, cells were incubated with a mixture of FAT1 primary antibody (ab190242; Abcam, UK) and GAPDH primary antibody (60004-1-lg; Proteintech Group, China) overnight at 4 °C. Then, cells were washed with PBST and were incubated with 680 nm and 800 nm infrared-labeled secondary antibody solutions (LI-COR Biosciences, USA) for 1 h at room temperature. Fluorescent signals for FAT1 and GAPDH were captured using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, Nebraska, USA). Finally, the relative abundance of the FAT1 protein was normalized to GAPDH.

Transwell migration/invasion assays {#s02.08}
-----------------------------------

Transwell migration and invasion assays were performed using a Transwell plate (Corning, New York, USA) that was coated with (for invasion) or without (for migration) Matrigel Basement Membrane Matrix (BD). Briefly, 1.5×10^5^ cells were seeded into the upper chamber of Transwell with serum-free medium, while culture medium with 20% FBS was added to the lower chamber. After culturing for 12−24 h, cells that migrated or invaded though the membrane were fixed with methanol for 10 min, stained with crystal violet solution for 5 min and finally photographed under a microscope (Leica, Germany).

Colony formation assay {#s02.09}
----------------------

A total of 1,000−3,000 transfected cells per well were seeded into plates containing medium with 10% FBS on d 0, and the cells were incubated at 37 °C with 5% CO~2~ for 14 d. On d 14, the cells were washed with PBS, fixed with methanol for 10 min and then stained with crystal violet solution for another 10 min. After washing with water and drying at room temperature, the colonies were photographed and counted.

RNA sequencing (RNA-seq) {#s02.10}
------------------------

The transcriptome sequencing profiles of KSYE30-control and KYSE30-siFAT1 cells were obtained to detect the altered expression of downstream genes. Briefly, sequencing libraries were constructed with NEBNext Ultra RNA Library Prep Kit for Illumina (NEB, Ipswich, USA) according to manufacturer's protocols. The libraries were sequenced on the Illumina HiSeq platform by Novogene (Beijing, China). Clean data were then mapped to the human reference genome hg19. The Fragments Per Kilobase of exon per Million mapped fragments (FPKM) of each gene was calculated and differential expression analysis was performed. The significantly differentially expressed genes between the control cells and the FAT1 depleted cells were input to DAVID database ([@b33],[@b34]) and enriched using Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b35]) and Gene Ontology (GO) analyses.

Statistical analysis {#s02.11}
--------------------
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}{}$\large \overline{{x}}{{±}}{{s}}_{\overline{{x}}}$\end{document}$. P\<0.05 was considered statistically significant. The data were statistically analyzed using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) by means of a two-sided Student's*t*-test.

Results {#s03}
=======

FAT1 exhibits a high frequency of genetic alterations in ESCC {#s03.01}
-------------------------------------------------------------

To comprehensively explore the genetic alterations of *FAT1* in ESCC, we first analyzed the somatic mutations of *FAT1* from a study by Du *et al*. ([@b36]), which consisted of a total of 41 whole-genome sequences and 449 whole-exome sequences from seven published ESCC genomic data ([@b7]-[@b10],[@b37]-[@b39]). We observed that *FAT1* was frequently mutated in ESCC (*[Figure 1A](#Figure1){ref-type="fig"}*). The mutation rate of *FAT1* was 10% (49/490), and most of the mutations, including missense, truncating or inframe, occurred in the cadherin domains.

![*FAT1* exhibits genetic alterations with high frequency in esophageal squamous cell carcinoma (ESCC). (A) Frequency of *FAT1* mutations in ESCC. Green box, cadherin domain; Red box, laminin G-like domain; Blue box, epidermal growth factor (EGF)-like domain; Yellow box, calcium-binding EGF domain; Black ball, truncating mutation; Green ball, missense mutation; Brown ball, inframe mutation; Pink ball, other mutation; (B) Frequency of *FAT*1 copy number variants (CNVs) in three types of squamous cell carcinomas and tumor cell lines. The percentage represents the approximate ratio of CNVs. Red box, amplification; Blue box, deletion. LUSCC, lung squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; TC, tumor cell lines.](cjcr-31-4-609-1){#Figure1}

Furthermore, we analyzed the CNV features of *FAT1* in 154 ESCC patients from our previous studies ([@b7],[@b10]) and found that CNVs of *FAT1* were altered in ESCC (*[Figure 1B](#Figure1){ref-type="fig"}*). The total CNV rate, including the amplification of 1/154 (0.6%) and the deletion of 18/154 (11.7%), was approximately 12.3% (19/154). We also consulted The Cancer Genome Atlas (TCGA) database ([@b40]) and observed similar CNV features for *FAT1* in lung squamous cell carcinoma (LUSCC) and head and neck squamous cell carcinoma (HNSCC) using the cBioPortal ([@b41],[@b42]) (*[Figure 1B](#Figure1){ref-type="fig"}*). In LUSCC, the total CNV rate was approximately 6.8% (34/501), consisting of the amplification of 3/501 (0.6%) and the deletion of 31/501 (6.2%). Consistently, in HNSCC, the total CNV rate was approximately 7.9% (41/522), consisting of the amplification of 3/522 (0.6%) and the deletion of 38/522 (7.3%). In addition, we analyzed the CNV rate of *FAT1* in 995 tumor cell lines (TC) from the Cancer Cell Line Encyclopedia (CCLE) database ([@b43]) using the cBioPortal and found that the total CNV rate of *FAT1* in the pan tumor cell lines was approximately 7.2% (72/995), including the amplification of 16/995 (1.6%) and the deletion of 56/995 (5.6%) (*[Figure 1B](#Figure1){ref-type="fig"}*). Taken together, our results revealed frequent inactivation of *FAT1* via mutations or deletions in ESCC and multiple other human cancers.

FAT1 expression is regulated by transcription factor E2F1 {#s03.02}
---------------------------------------------------------

It is reported that *FAT1* expression is downregulated in ESCC tissues ([@b9],[@b13],[@b14]). In addition to the genetic alterations described above, we hypothesized that transcriptional regulation may also play an important role in this process. To test this, we consulted the encyclopedia of DNA elements (ENCODE) database ([@b44]) and observed a putative binding site for the transcription factor E2F1 on the promoter region of *FAT1* with the following identifiers: ENCFF000XCY, ENCFF000XEQ and ENCFF000ZLB (*[Figure 2A](#Figure2){ref-type="fig"}*). Thus, a ChIP assay, using an E2F1 antibody, was then employed to confirm this occupancy. As expected, we observed a strong enrichment of E2F1 at the promoter region of *FAT1* when compared with that in IgG control (*[Figure 2B](#Figure2){ref-type="fig"}*).

![E2F1 regulates *FAT1* transcription. (A) Putative binding sites of E2F1 on the *FAT1* promoter region from different cohorts in encyclopedia of DNA elements (ENCODE) database. Red box represents binding reads of E2F1; (B) Enrichment of E2F1 on *FAT*1 promoter in KYSE30 cells shown by chromatin immunoprecipitation (ChIP) and quantitative polymerase chain reaction (qPCR). Enrichment is determined as the amount of *FAT1* promoter associated to E2F1 relative to immunoglobulin G (IgG) control; (C) Luciferase activity of pGL3-FAT1 vector was measured in KYSE30 cells upon E2F1 knockdown. Data are presented as ratio of the firefly luciferase activity to Renilla luciferase activity; RT-qPCR (D) and Western blot (E) analyses of E2F1 expression in KYSE30 cells upon E2F1 knockdown. Relative RNA levels of E2F1 were normalized to endogenous GAPDH; (F) RT-qPCR analysis of *FAT1* expression in KYSE30 cells as described in (D). Relative RNA levels of *FAT1* were normalized to endogenous GAPDH. \*, P\<0.05; \*\*, P\<0.01; \*\*\*, P\<0.001*vs*. control.](cjcr-31-4-609-2){#Figure2}

To ascertain whether E2F1 regulates the transcription of *FAT1*, we constructed a luciferase reporter, namely pGL3-FAT1, which contained the promoter region of *FAT1*. The luciferase activity of pGL3-FAT1 was much higher than the control vector upon transfection into KYSE30 cells, and this increased luciferase activity was inhibited by siRNA-mediated E2F1 knockdown (*[Figure 2C](#Figure2){ref-type="fig"}*). Meanwhile, knockdown of E2F1 reduced *FAT1* mRNA levels in KYSE30 cells (*[Figure 2F](#Figure2){ref-type="fig"}*). The knockdown efficiency of E2F1 at the mRNA and protein levels was confirmed by RT-qPCR (*[Figure 2D](#Figure2){ref-type="fig"}*) and Western blot (*[Figure 2E](#Figure2){ref-type="fig"}*), respectively. Collectively, these results showed that E2F1 binds to the *FAT1* promoter to activate its transcription in ESCC cells.

Downregulation of FAT1 promotes ESCC cell proliferation, migration and invasion {#s03.03}
-------------------------------------------------------------------------------

To explore the biological roles of *FAT1*, we performed a loss-of-function study using two small interfering RNAs (siRNAs) to knock down the *FAT1* in KYSE30 and KYSE150 cell lines. RT-qPCR and In-cell western assays showed that the two siRNAs effectively downregulated both mRNA and protein levels of *FAT1*, when compared with the control siRNA (*[Figure 3A,B](#Figure3){ref-type="fig"}*). The colony formation and Transwell assays were used to elucidate the effects of *FAT1* knockdown on ESCC cell proliferation, migration and invasion. As shown in *[Figure 3C,D](#Figure3){ref-type="fig"}*, the cells transfected with siRNAs targeting *FAT1* exhibited an enhanced colony formation ability compared with the control siRNA transfected cells. Taking advantage of the Transwell system, we validated that knockdown of *FAT1* enhanced the migration and invasion abilities of KYSE30 and KYSE150 cells (*[Figure 3E-H](#Figure3){ref-type="fig"}*). Taken together, these results demonstrated that *FAT1* knockdown strengthened the aggressive potential of ESCC cells.

![*FAT1* knockdown promotes KYSE30 and KYSE150 cell migration, invasion and proliferation. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) (A) and In-cell western analyses (B) of *FAT1* expression in KYSE30 and KYSE150 cells upon *FAT1* knockdown. Relative RNA and protein levels of *FAT1* were normalized to endogenous GAPDH; (C, D) KYSE30 and KYSE150 cells were transfected with the indicated siRNAs. After 24 h of transfection, cells were subject to colony formation assay. Representative results (C) and corresponding quantification (D) are shown (Scale bar =2 mm); (E−H) Representative results of Transwell migration/invasion assays and corresponding quantification in KYSE30 (E, F) and KYSE150 (G, H) cells after transfected with indicated siRNAs as described in (C, D) (Scale bar =100 μm). \*, P\<0.05; \*\*, P\<0.01; \*\*\*, P\<0.001*vs*. control.](cjcr-31-4-609-3){#Figure3}

Overexpression of FAT1 inhibits ESCC cell proliferation, migration and invasion {#s03.04}
-------------------------------------------------------------------------------

To test the gain-of-function of *FAT1* in ESCC cell lines, we transfected *FAT1* into KYSE30 and KYSE410 cell lines using an expression vector with all the key functional domains of FAT1 (truncated FAT1, which was named FAT1-Trunc) ([@b18]). The mRNA and protein levels of *FAT1* were monitored by RT-qPCR and In-cell western assays, respectively (*[Figure 4A,B](#Figure4){ref-type="fig"}*). *FAT1* overexpression reduced the colony formation abilities of KYSE30 and KYSE410 cells compared with the control empty vector (*[Figure 4C,D](#Figure4){ref-type="fig"}*). Furthermore, the Transwell assays revealed that *FAT1* overexpression greatly attenuated the migration and invasion abilities of KYSE30 and KYSE410 cells (*[Figure 4E-H](#Figure4){ref-type="fig"}*). Collectively, the results of both the loss-of-function and gain-of-function studies demonstrated that *FAT1* may act as a tumor suppressor in ESCC.

![*FAT1* overexpression suppresses KYSE30 and KYSE410 cell proliferation, migration and invasion. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) (A) and In-cell western analyses (B) of FAT1 expression in KYSE30 and KYSE410 cells upon *FAT1* overexpression. Relative RNA and protein levels of *FAT1* were normalized to endogenous GAPDH; (C, D) KYSE30 and KYSE410 cells were transfected with indicated vectors. After 24 h of transfection, cells were subject to colony formation assay. Representative results (C) and corresponding quantification (D) are shown (Scale bar =4 mm); (E−H) Representative results of Transwell migration/invasion assays and the corresponding quantification in KYSE30 (E, F) and KYSE410 (G, H) cells after transfected with the indicated vectors as described in (C, D) (Scale bar =100 μm). \*, P\<0.05; \*\*, P\<0.01; \*\*\*, P\<0.001*vs*. control.](cjcr-31-4-609-4){#Figure4}

FAT1 is involved in mitogen-activated protein kinase (MAPK) signaling pathway and cell adhesion process in ESCC cells {#s03.05}
---------------------------------------------------------------------------------------------------------------------

To investigate the molecular mechanism of *FAT1* in ESCC oncogenesis, we performed a RNA-seq analysis using control and *FAT1* knocked-down KYSE30 cells, and subsequently analyzed the altered gene expression profiles (*[Supplementary Table S2](#TableS2){ref-type="table"}*). The KEGG pathway enrichment analysis revealed that upon *FAT1* knockdown, the significantly differentially expressed genes were enriched in multiple pathways, including the MAPK signaling pathway and cell adhesion molecules (CAMs) (*[Figure 5A](#Figure5){ref-type="fig"}*). The GO functional analysis showed that these genes were enriched in biological processes, including the cell adhesion, cell-cell signaling and epidermis development (*[Figure 5B](#Figure5){ref-type="fig"}*). Genes involved in the MAPK signaling pathway and the cell adhesion process were selected and validated by RT-qPCR after the knockdown of *FAT1* in KYSE30 cells. As expected, *FAT1* knockdown induced the mRNA levels of *MAP3K8*, *MAP2K2* and *MAP2K6* and decreased the mRNA level of MAPK inactivator DUSP6 (*[Figure 5C](#Figure5){ref-type="fig"}*). Meanwhile, *FAT1* knockdown enhanced the mRNA levels of *L1CAM* and *CDH5*, which are involved in the cell adhesion process (*[Figure 5D](#Figure5){ref-type="fig"}*). In conclusion, these results indicated that *FAT1* is involved in the MAPK signaling pathway and the cell adhesion process in ESCC cells.

###### 

Top 100 significantly differentially expressed genes (P\<0.05) in*FAT1* knocked-down KYSE30 cells

  ---------------------------------------------------------------------------------------------------------------------------
  Gene ID           Gene_name          Gene_locus               siFAT_FPKM   siCtrl_FPKM   Log2 fold\   P          Padj
                                                                                           change                  
  ----------------- ------------------ ------------------------ ------------ ------------- ------------ ---------- ----------
  ENSG00000172062   *SMN1*             5:70220768−70249769      5.409958     51.32826      −3.25018     9.20E-13   2.11E-08

  ENSG00000228589   *SPCS2P4*          1:28421582−28422933      1.704209     16.4227       −3.27085     5.89E-12   6.76E-08

  ENSG00000094755   *GABRP*            5:170190354−170241051    2.248404     0.139269      3.985165     3.52E-10   2.69E-06

  ENSG00000233013   *FAM157B*          9:141106637−141143444    0.141909     1.719214      −3.58454     2.44E-09   1.40E-05

  ENSG00000144857   *BOC*              3:112929850−113006303    1.273603     0.11785       3.411765     2.95E-08   0.000136

  ENSG00000226054   *MEMO1P1*          21:37502669−37504208     10.44055     1.85337       2.48752      6.49E-08   0.000237

  ENSG00000180673   *EXOC5P1*          4:63682544−63684512      0.553869     0.013287      5.217273     7.22E-08   0.000237

  ENSG00000114854   *TNNC1*            3:52485118−52488086      2.043411     0.088238      4.448301     1.15E-07   0.00033

  ENSG00000188199   *NUTM2B*           10:81462983−81474437     0.40364      0.017786      4.419231     1.52E-07   0.000387

  ENSG00000272343   *RP11-140I16.3*    8:57135247−57135732      1.495978     0             7.856664     7.40E-07   0.0017

  ENSG00000169627   *BOLA2B*           16:30204255−30205627     6.462627     28.7566       −2.15757     1.28E-06   0.002682

  ENSG00000251070   *BMS1P6*           10:48187416−48199256     0.491616     0             7.705352     2.40E-06   0.0046

  ENSG00000225465   *RFPL1S*           22:29832818−29874164     0.526845     0.058036      3.147156     8.67E-06   0.015322

  ENSG00000009724   *MASP2*            1:11086580−11107290      0.63512      0.05413       3.496074     1.26E-05   0.020666

  ENSG00000139899   *CBLN3*            14:24895738−24900160     0.806774     0.102465      2.947334     1.47E-05   0.021116

  ENSG00000166268   *MYRFL*            12:70219084−70352877     0.398282     0.026058      3.850765     1.47E-05   0.021116

  ENSG00000147573   *TRIM55*           8:67039131−67087720      0.012702     0.356515      −4.646       1.58E-05   0.021279

  ENSG00000186442   *KRT3*             12:53183469−53189901     0.565061     0.079075      2.811247     1.83E-05   0.022482

  ENSG00000183783   *KCTD8*            4:44175926−44450824      0.349388     0             7.411466     1.96E-05   0.022482

  ENSG00000237938   *RP11-288I21.1*    1:16049214−16063391      0.826615     0             7.411466     1.96E-05   0.022482

  ENSG00000152726   *FAM21B*           10:47894023−47949412     0.219917     1.016119      −2.20698     2.83E-05   0.030915

  ENSG00000130635   *COL5A1*           9:137533620−137736686    2.739808     0.699106      1.963217     3.32E-05   0.033136

  ENSG00000109511   *ANXA10*           4:169013666−169108841    0.025271     0.654749      −4.53108     3.37E-05   0.033136

  ENSG00000197409   *HIST1H3D*         6:26197068−26199521      3.076838     0.574103      2.407265     3.46E-05   0.033136

  ENSG00000020181   *GPR124*           8:37641709−37702414      0.360846     0.056548      2.652953     3.61E-05   0.033166

  ENSG00000271815   *CTD-2235C13.3*    5:74659585−74660067      0            0.975007      −7.23828     4.78E-05   0.042186

  ENSG00000198576   *ARC*              8:143692405−143696833    0.589737     0.096098      2.594743     5.29E-05   0.044146

  ENSG00000174498   *IGDCC3*           15:65619465−65670378     1.223256     0.248577      2.285585     5.38E-05   0.044146

  ENSG00000183793   *NPIPA5*           16:15457516−15474904     0.177824     1.234089      −2.77703     5.82E-05   0.045299

  ENSG00000150165   *ANXA8L1*          10:47157983−47174093     0.408894     1.765685      −2.1097      5.92E-05   0.045299

  ENSG00000202198   *RN7SK*            6:52860418−52860748      4.539458     0.790414      2.50285      7.11E-05   0.048664

  ENSG00000037280   *FLT4*             5:180028506−180076624    0.010123     0.240426      −4.4062      7.35E-05   0.048664

  ENSG00000236617   *RP11−46H11.12*    12:133464428−133465169   1.047994     0.04714       4.314013     7.35E-05   0.048664

  ENSG00000255967   *RP11−438L7.3*     12:8786963−8790204       0.254545     0.01145       4.314013     7.35E-05   0.048664

  ENSG00000259804   *CTD−2012K14.7*    16:67595314−67596212     0.512194     0             7.2013       7.55E-05   0.048664

  ENSG00000259243   *GOLGA6L19*        15:83011379−83018198     0.750822     0.090061      3.017247     7.63E-05   0.048664

  ENSG00000183578   *TNFAIP8L3*        15:51348795−51397473     0.299989     0.023132      3.614736     8.17E-05   0.049821

  ENSG00000101222   *SPEF1*            20:3758151−3762095       0.597876     0.090061      2.701856     8.24E-05   0.049821

  ENSG00000269990   *CTD−3074O7.12*    11:66303369−66305407     2.008676     0.538908      1.890325     0.000104   0.060948

  ENSG00000083857   *FAT1*             4:187508937−187647876    43.28378     133.7042      −1.63191     0.000107   0.061382

  ENSG00000269054   *CTD−2619J13.3*    19:58873951−58877958     0.705572     0.033117      4.252951     0.00011    0.061382

  ENSG00000233337   *UBE2FP3*          1:111980136−111980659    0            0.798861      −7.06955     0.00012    0.063304

  ENSG00000273156   *RP11−127B20.2*    4:83266029−83266693      0.655981     0             7.123842     0.00012    0.063304

  ENSG00000245711   *NADK2−AS1*        5:36221157−36222004      0.168298     1.308135      −2.931       0.000121   0.063304

  ENSG00000205683   *DPF3*             14:73086004−73360809     0.207135     1.024892      −2.29923     0.000127   0.064657

  ENSG00000169174   *PCSK9*            1:55505221−55530525      2.306266     0.668728      1.779379     0.000135   0.067382

  ENSG00000261597   *RP11−353B9.1*     15:49944336−49948429     0.023678     0.204496      −3.07449     0.000138   0.067382

  ENSG00000111341   *MGP*              12:15034115−15038860     36.15032     11.74596      1.616772     0.000157   0.073872

  ENSG00000174194   *AGAP8*            10:51224681−51371321     0.900366     0.161998      2.452153     0.000163   0.073872

  ENSG00000174521   *TTC9B*            19:40721965−40724306     0.015309     0.330546      −4.26948     0.000164   0.073872

  ENSG00000236431   *AC009237.11*      2:96201865−96202243      1.406772     0.069031      4.189189     0.000164   0.073872

  ENSG00000088053   *GP6*              19:55525073−55549632     0.371744     0.03087       3.508334     0.000167   0.073872

  ENSG00000169583   *CLIC3*            9:139889087−139891255    29.72199     9.6876        1.612147     0.000177   0.076852

  ENSG00000214940   *NPIPA8*           16:18411799−18441131     0.291042     1.135932      −1.96402     0.000191   0.0811

  ENSG00000112541   *PDE10A*           6:165740776−166400091    0.541212     1.73594       −1.68501     0.000196   0.081985

  ENSG00000179044   *EXOC3L1*          16:67218269−67224107     0.556412     0.083427      2.703749     0.000211   0.085184

  ENSG00000260604   *RP1−140K8.5*      6:3905144−3912213        0.123402     0.018503      2.703749     0.000211   0.085184

  ENSG00000234231   *AC093616.4*       2:88000503−88038766      0.638541     2.228317      −1.8048      0.000228   0.087622

  ENSG00000102385   *DRP2*             X:100474758−100519486    0.007813     0.096993      −3.55545     0.000241   0.087622

  ENSG00000136449   *MYCBPAP*          17:48585745−48608862     0.037028     0.459696      −3.55545     0.000241   0.087622

  ENSG00000222020   *AC062017.1*       2:240323130−240324058    0.115956     1.439574      −3.55545     0.000241   0.087622

  ENSG00000269896   *RP4−740C4.6*      1:2281853−2284259        0.815548     0.19565       2.047422     0.000244   0.087622

  ENSG00000177694   *NAALADL2*         3:174156363−175523428    0.849999     0.149379      2.483511     0.000246   0.087622

  ENSG00000166592   *RRAD*             16:66955582−66959547     0.550792     0.028315      4.122478     0.000248   0.087622

  ENSG00000268650   *AC068499.10*      19:18315540−18331290     0.994008     0.051099      4.122478     0.000248   0.087622

  ENSG00000144583   *4−Mar*            2:217122588−217236750    0.877403     2.64745       −1.59731     0.000276   0.094002

  ENSG00000263320   *RP11−498D10.6*    16:71963914−71965102     0.713389     0.11002       2.663255     0.00028    0.094002

  ENSG00000180596   *HIST1H2BC*        6:26115101−26124154      12.72822     4.083932      1.633976     0.000291   0.094002

  ENSG00000090661   *CERS4*            19:8271620−8327305       3.35701      0.968069      1.786044     0.000292   0.094002

  ENSG00000261655   *CTD−3064M3.3*     8:142363503−142365465    0.345683     0.039984      3.057257     0.0003     0.094002

  ENSG00000146070   *PLA2G7*           6:46671938−46703430      0.222066     0             6.862874     0.000315   0.094002

  ENSG00000164509   *IL31RA*           5:55147207−55218678      0            0.160836      −6.97715     0.000315   0.094002

  ENSG00000223979   *SMCR2*            17:17577340−17581002     0.644544     0             6.862874     0.000315   0.094002

  ENSG00000255585   *RP11−188C12.2*    9:140682117−140683139    0.35535      0             6.862874     0.000315   0.094002

  ENSG00000269846   *RBL1*             20:35724188−35725581     0            0.281521      −6.97715     0.000315   0.094002

  ENSG00000269903   *RP11−571M6.18*    12:58208277−58208709     0            0.906329      −6.97715     0.000315   0.094002

  ENSG00000271803   *RP1−63M2.5*       20:32262323−32263186     0.826188     0             6.862874     0.000315   0.094002

  ENSG00000260051   *LA16c−390E6.4*    16:1501761−1502654       0.425173     2.019576      −2.23803     0.000333   0.097904

  ENSG00000142920   *ADC*              1:33546705−33586131      0.950682     0.211778      2.151327     0.000338   0.098341

  ENSG00000228137   *AP001469.7*       21:47666804−47667596     1.491375     0.134168      3.393454     0.000349   0.098807

  ENSG00000253559   *OSGEPL1−AS1*      2:190627430−190630282    1.077104     0.096899      3.393454     0.000349   0.098807

  ENSG00000120738   *EGR1*             5:137801179−137805004    4.139541     1.392342      1.566469     0.000355   0.099482

  ENSG00000169282   *KCNAB1*           3:155755490−156256545    0.595795     0.094587      2.621592     0.000372   0.102948

  ENSG00000269951   *RP11−797A18.6*    15:77359996−77360667     0.036064     0.700786      −4.11843     0.000377   0.102948

  ENSG00000171873   *ADRA1D*           20:4201329−4229721       2.924115     0.967541      1.589637     0.000406   0.109612

  ENSG00000121966   *CXCR4*            2:136871919−136875735    0.158022     0.713387      −2.16617     0.000416   0.109612

  ENSG00000262691   *CTC−277H1.7*      16:67295011−67297687     0.244431     0.029319      3.005036     0.000419   0.109612

  ENSG00000263740   *RN7SL4P*          3:15780022−15780315      1.813492     6.852133      −1.91633     0.00042    0.109612

  ENSG00000134258   *VTCN1*            1:117686209−117753556    17.60335     6.175808      1.50607      0.000425   0.109728

  ENSG00000163623   *NKX6−1*           4:85413140−85419603      0.743832     0.184474      1.999144     0.000444   0.113408

  ENSG00000235169   *SMIM1*            1:3689352−3692546        3.280273     0.792809      2.035269     0.000462   0.116388

  ENSG00000224419   *KRT18P27*         13:90882638−90883936     0.074626     0.563938      −2.88262     0.000466   0.116388

  ENSG00000271780   *RP11−1017G21.5*   14:102414684−102415762   0.112302     0.751662      −2.71604     0.000495   0.121711

  ENSG00000247627   *MTND4P12*         5:134262350−134263726    1.777574     5.281938      −1.57473     0.000503   0.121711

  ENSG00000167588   *GPD1*             12:50497602−50505102     0.480519     0.045108      3.332392     0.000507   0.121711

  ENSG00000215912   *TTC34*            1:2567415−2718286        0            0.173674      −6.87843     0.000517   0.121711

  ENSG00000273448   *RP11−166O4.6*     7:66798034−66799370      0.253768     0             6.764224     0.000517   0.121711

  ENSG00000253570   *RNF5P1*           8:38458179−38458718      0.314155     1.792629      −2.49545     0.000519   0.121711

  ENSG00000255248   *RP11−166D19.1*    11:121899063−121987031   0.374941     1.379889      −1.87842     0.000552   0.128131

  ENSG00000165125   *TRPV6*            7:142568956−142583507    0.559696     0.130914      2.081086     0.000573   0.130824
  ---------------------------------------------------------------------------------------------------------------------------

![Global transcriptional identification of genes regulated by *FAT1*. KYSE30 cells were transfected with *FAT1* siRNA or scramble control siRNA. After 48 h of transfection, cells were collected and subject to RNA-seq. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (A) and Gene Ontology (GO) functional analysis (B) of significantly differently expressed genes upon *FAT1* knockdown in KYSE30 cells; Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) showing the expression of genes involved in mitogen-activated protein kinase (MAPK) signal pathway (C) and cell adhesion process in KYSE30 cells after 48 h of transfection with the indicated siRNAs (D). Relative RNA levels of genes were normalized to endogenous GAPDH. \*, P\<0.05; \*\*, P\<0.01; \*\*\*, P\<0.001*vs*. control.](cjcr-31-4-609-5){#Figure5}

Discussion {#s04}
==========

ESCC is one of the most prevalent malignant tumors in China, with an elusive cancerogenesis and a poor prognosis ([@b3],[@b6]). To study the molecular mechanism of ESCC tumorigenesis, several large-scale genomic sequencing studies have attempted to uncover the driving genomic variations ([@b7]-[@b11]). Interestingly, *FAT1* is frequently subject to inactivating mutations in ESCC ([@b8]-[@b11]), which is accompanied by loss of heterozygosity or homozygous deletion ([@b9],[@b11]). Given that the case number of ESCC in each of these studies is relatively small, we analyzed the mutations of *FAT1* by using data that was combined from different cohorts by Du *et al*. ([@b36]) and revealed that *FAT1* was indeed frequently mutated in ESCC. Furthermore, we analyzed the *FAT1* CNV using our previous data ([@b7],[@b10]) and databases, and the results showed a deletion of *FAT1* in ESCC and other cancers. Although the function of *FAT1* in tumorigenesis is still under debate in different types of tumors ([@b18]-[@b21]), it is considered a tumor suppressor gene in ESCC ([@b9],[@b13],[@b14]). Consistently, in this study, the *in vitro* experiments revealed that upregulation of *FAT1* inhibited ESCC cell proliferation, migration and invasion, while *FAT1* exhaustion resulted in the opposite effects. Thus, our study supplements the current theories that *FAT1* shows mutations and deletions in ESCC and acts as a tumor suppressor gene.

In addition to the dysregulation caused by the genetic alterations, an alternative possibility is that transcription is changed during tumorigenesis. To illustrate the transcriptional regulation of *FAT1* mRNA expression in ESCC cells, we consulted the ENCODE database and found that the *FAT1* promoter region was occupied by transcription factor E2F1 in several ChIP-seq projects. E2F1 is an important transcription factor that regulates the gene expression in multiple types of human cancers and has both oncogenic and tumor-suppressive properties ([@b45]-[@b48]). Matrix metalloproteinase (*MMP*) genes are direct transcriptional targets of E2F1 in non-small cell lung cancer (NSCLC) cell lines ([@b49]). E2F1 binds to the promoter region of the phosphatase of activated cells 1 (*PAC1*) and actives its transcription in breast cancer cells ([@b50]). Nevertheless, little is known about the transcriptional regulatory effects of E2F1 in ESCC. Here, we characterized the binding and transcription activity of E2F1 upon the *FAT1* promoter region, as well as the influence of E2F1 on *FAT1* mRNA levels, and thus identified *FAT1* as a transcriptional target of E2F1 in ESCC cells.

The results of RNA-seq and RT-qPCR revealed that *FAT1* knockdown resulted in the altered expression of package of genes that are involved in the MAPK signaling pathway, which is consistent with previous report ([@b13]). The MAPK signaling pathway is an important signaling component that consists of a set of evolutionarily conserved kinase cascades from yeast to human, including MAPK kinase kinase kinase (MKKK), MAPK kinase kinase (MKK) and MAPK ([@b51],[@b52]). It is reported that the MAPK pathway is dysregulated in ESCC and may function as an oncogene in ESCC tumorigenesis ([@b53],[@b54]). On the other hand, the GO functional analysis and RT-qPCR also revealed that loss of *FAT1* subsequently upregulated the expression of genes that participate in the cell adhesion process, including *L1CAM* and *CHD5*, which may play roles in the progression or metastasis of multiple cancers and correlate with poor outcomes ([@b55]-[@b58]). Collectively, the RNA-seq results revealed that *FAT1* knockdown led to the abnormal expression of genes in the MAPK signaling pathway and cell adhesion process, further indicating that *FAT1* is involved in ESCC tumorigenesis

Conclusions {#s05}
===========

In this study we identified *FAT1* as the transcriptional target of E2F1. Moreover, we also validated that *FAT1* exhibits tumor suppressive function in ESCC and participates in the MAPK signaling pathway and cell adhesion process. These results advance our understanding of mechanisms by which *FAT1* is inactive and regulated in ESCC, and the data also highlight the importance of *FAT1* in ESCC tumorigenesis.
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